Tumour necrosis factor (TNF) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA) and it has been shown that the TNF-lymphotoxin (TNF-LT) region influences susceptibility to RA. To investigate the role of the TNF-LT locus further, inheritance of TNF 5Ј promoter alleles was determined in multiplex RA families. Six previously defined TNF promoter single nucleotide polymorphisms (SNPs) (−238, −308, −376, −857, −863, −1031) were observed in these families and in addition, a heretofore undocumented adenine (A) to cytosine (C) substitution at position −572 relative to the transcription start site was defined. TNF 5Ј promoter SNPs were found to co-segregate with specific TNF microsatellite haplotypes. In particular, the SNP −308A allele was found to be inherited with the TNF a2, b3, c1, d1, e3 (H2) microsatellite haplotype (P Ͻ 0.001) which had previously been found to be associated with RA in individuals heterozygous for the HLA-DR 'shared epitope' (SE). When the data were stratified by the presence of the SE with further stratification according to SE DR subtypes and analysed by transmission disequilibrium test (TDT) for which offspring were assumed independent, the −308A and −857T alleles were found to be associated with RA in patients carrying the SE (P = 0.0076 and 0.0063 respectively). The data were further stratified to analyse for association in individuals homozygous or heterozygous for SE alleles. Results showed that the −308A allele was significantly associated with RA susceptibility in individuals heterozygous for the SE (P Ͻ 0.001) with the significance only occurring in patients carrying HLA-DR4 (P Ͻ 0.001), while the −857T allele was significant in individuals homozygous for the SE (P = 0.0039). Further analysis using the pedigree disequilibrium test (PDT) which conservatively adjusts for all sources of familial correlation except that conferred by linkage disequilibrium still indicated a significant role for the −308A and −857T alleles. These data provide evidence that TNF promoter SNPs may play an independent role in RA susceptibility in specific immunogenetically-defined groups of RA patients. Genes and Immunity (2001) 2, 82-87.
Introduction
Rheumatoid arthritis (RA) is a common, chronic inflammatory disorder with a prevalence of 1% in most populations. 1 Much clinical and experimental evidence exists for the pivotal role of tumour necrosis factor (TNF) in RA pathogenesis. 2 TNF, a pro-inflammatory cytokine is found at elevated levels in the pannus, the region of tissue damage in the RA joint. 3 TNF, synergistically with interleukin-1, induces a cytokine cascade which results in the production of matrix metalloproteinases. 4 These matrix metalloproteinases are directly responsible for the erosive changes characteristic of the disease. 5 Furthermore, overexpression of human TNF alone in transgenic mice can induce a polyarthritis similar to RA. 6 In humans, anti-TNF treatment using chimeric anti-TNF antibody reduced TNF levels and produced marked clinical benefit in a multicentre, randomised, placebocontrolled, double-blind trial. 7, 8 A similar study with a recombinant human TNF receptor (p75)-Fc fusion protein as an antagonist to TNF has also produced significant improvement in the disease status of RA patients. 9 In both cases, withdrawal of anti-TNF therapy was associated with a return of disease activity. Therefore it appears that the benefit of anti-TNF therapy is dependent on continual suppression of TNF, indicating the chronic production of TNF during the disease.
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RA is a multifactorial disease with both genetic and environmental factors contributing to susceptibility. Genetic analysis of RA susceptibility suggests a polygenic inheritance with the largest contribution from the major histocompatibility complex (MHC). 10, 11 Part of the MHC genetic contribution to RA is provided by several alleles of the HLA-DRB1 gene located in the MHC class II region (6p21). 12 In particular, the HLA-DRB1*04 and HLA-DRB1*01 alleles of the HLA-DRB1 gene have been associated with RA, while the HLA-DRB1*02 was not. 13 An explanation for the association of HLA-DRB1*04 and HLA-DRB1*01 alleles with RA has been proposed in the 'shared epitope' (SE) hypothesis.
14 However, the HLA-DR SE does not account for the total MHC genetic contribution to RA 15 and may be primarily associated with severe forms of the disease. 4 Another MHC contribution to RA is provided by the TNF-lymphotoxin (LT) locus, 16, 17 in a region recently re-classified as the class IV region of the MHC (previously class III). 18 The important physiological role TNF plays in RA, and the location of the TNF gene within the MHC has led to speculation about the role the TNF gene itself may play in RA. Microsatellite markers flanking and within the TNF-LT locus (6p21) 19 have been used to demonstrate that two extended TNF microsatellite haplotypes (incorporating alleles from all five marker microsatellites) are associated with RA susceptibility. The TNF a6, b5, c1, d3, e3 (H1) haplotype was associated with RA in individuals homozygous for the SE and the TNF a2, b3, c1, d1, e3 (H2) haplotype was associated with RA in individuals heterozygous for the SE. This analysis has indicated that genetic effects, distinct from HLA-SE, influencing susceptibility to RA, are provided by genes located in the MHC class III-IV regions. 16 These findings have been confirmed independently by three other groups. 17, 20, 21 The TNF gene itself is an obvious candidate for investigation.
The TNF gene is tightly regulated at several levels, ie at the transcriptional, post-transcriptional, translational and post-translational levels. Transcriptional regulation of the TNF gene is mediated via the 5Ј promoter while posttranscriptional regulation is via the 3Ј untranslated region (3Ј UTR). 22 However, a recent study of TNF 3Ј UTR in RA patients and unaffected individuals failed to find any polymorphisms. 23 Thus, it appears that the human TNF 3Ј UTR is highly conserved and does not influence susceptibility to RA.
Several single nucleotide polymorphisms (SNPs) have been described in the TNF promoter located at positions −1031 (thiamine (T) to cytosine (C) substitution), 24 −863, −163 25 (all guanine (G) to A substitutions) and +70 (C insertion), 28 relative to the transcription start site. The functional role of these SNPs has been investigated and they have been individually shown to alter TNF transcription under certain stimulatory conditions. 24, [29] [30] [31] [32] [33] [34] In the current study, the nucleotide sequence of the TNF 5Ј promoter was analysed in RA affected and unaffected members of 33 multiplex RA families typed for the five TNF microsatellites and HLA-DR alleles. Using the TNF haplotype data (n = 33) it was possible to demonstrate the co-segregation of the TNF 5Ј promoter SNPs with specific RA and non-RA associated TNF haplotypes. In addition, the transmission disequilibrium test (TDT) 35, 36 and the pedigree disequilibrium test (PDT) 37 were used to investigate the association between 
Results
DNA sequence analysis identified seven TNF promoter SNPs at positions −238, −308, −376, −572, −857, −863 and −1031 relative to the transcription start site ( Figure 1 ) in these families. The adenine to cytosine substitution at position −572 has not been previously reported. In total 33 TNF microsatellite haplotypes were present in the sample. All TNF promoter SNPs displayed Mendelian inheritance with specific TNF microsatellites haplotypes ( Table 1 ). The −238A allele was present in 20 individuals from eight families and was found only to be associated with the TNF H19 microsatellite haplotype ( Table 1 ). The −308A allele was present in 76 individuals from 20 families and was observed to be significantly associated with either the TNF H2 (n = 64) haplotype or the TNF H22 (n = 12) haplotype. Previously, the TNF H2 haplotype has been demonstrated to influence susceptibility to RA in individuals heterozygous for the HLA-DR SE. 16 In this sample 15 individuals (nine affected, six unaffected) were found to be homozygous for the −308A allele. The −376A allele was only observed in a single individual carrying the rare TNF H4 haplotype. The −572C allele was only carried by five members of a single family and was inherited with the TNF H35 haplotype. The −857T allele was found in five families and to be associated with the TNF H39 haplotype (n = 21). The −863A and −1031C were always inherited together and were significantly associated with the TNF H8 microsatellite haplotype. Thus, with the exception of the SNPs at −863 and −1031, two or more TNF 5Ј SNPs were never found together on the same chromosome in this population. Furthermore, no rare TNF promoter SNP allele was inherited with the TNF H1 (a6, b5, c1, d3, e3) haplotype which has previously been associated with RA susceptibility. 16, 20 The transmission and disequilibrium tests (TDT/PDT) were used to investigate for preferential transmission of TNF promoter SNPs and HLA-DR SE from heterozygous parents to RA affected siblings. For the TDT, siblings were treated independently and significant associations between RA and the individual TNF promoter SNPs, −308A (P = 0.008) and −857T (P = 0.006) were observed ( Table 2 ). Further analysis using the PDT, which allowed for effects due to the linked but untyped MHC loci gave P-values of 0.0358 and 0.0196 respectively for the −308A and −857T SNPs. Due to linkage disequilibrium within the MHC but not with TNF promoter, the data were stratified by the presence or absence of the HLA-DR SE, with further stratification according to SE DR subtypes to determine if an additional genetic effect had been provided by any of the TNF promoter SNP alleles. The frequencies, among affected individuals, of DRB1*0101, DRB1*0401, DRB1*0404 and DRB1*0408 were 31, 68, 9 and 11% respectively. Because of the low frequencies of DRB1*0404 and DRB1*0408 in this population and the higher relative risks of DRB1*04 alleles compared with DRB1*0101, the data were stratified according to the presence of only DRB1*01, only DRB1*04 or DRB1*04 and DRB1*01 (among SE homozygotes). No significant associ- ations between the TNF SNPs and RA were observed in patients who did not possess the SE. However, in individuals possessing the SE significant associations were found between RA susceptibility and the −308A and −857T alleles (Table 2) . Furthermore, the −238A allele approached a significantly negative association with RA. The data were further stratified to analyse for allelic associations in individuals homozygous or heterozygous for the SE. The −308A SNP was found to be significantly associated with RA in individuals heterozygous for the SE (22T, 4NT; P Ͻ 0.001) with the significance only occurring in patients carrying HLA-DR4 (16T, 1NT; P Ͻ 0.001), while carriage of the −308A was not significant in SE homozygotes. Conversely, the −857T SNP was not sig-85 nificantly associated with RA in SE heterozygotes but was significant in individuals homozygous for the SE (DRB1*04 or DRB1*01) (9T, 0NT; P = 0.0039); this effect was noted both for HLA-DR4 homozygotes (4T, 0NT; P = 0.125) and for HLA-DR4/DR1 heterozygotes (5T, 0NT; P = 0.0625). Analysis using the PDT gave P-values of 0.0119 for association of −308A in SE heterozygous individuals and 0.0253 for association of −857T in SE homozygotes. These results suggested that several genetic effects may be provided by the TNF SNPs in a group of RA patients carrying the SE. To further investigate these effects, the risk ratio from carriage of TNF promoter SNPs was assessed in this group. The −308A allele was found to double the risk of RA (risk ratio (RR) = 2.7, 95% confidence interval (CI) (1.27, 6.25); P = 0.005).
Discussion
The role of the TNF promoter in RA susceptibility has been investigated in this study. By the use of RA multiplex families it was possible to demonstrate co-segregation of alleles of TNF 5Ј promoter SNPs and TNF microsatellite haplotypes. No TNF 5ЈSNP allele was found to be inherited with the RA associated H1 TNF haplotype but the −308A SNP allele was inherited with the H2 TNF haplotype. This association between the TNF 5Ј promoter SNP −308A allele and the TNF H2 microsatellite haplotype was not unexpected, since both have previously been shown to be inherited as part of the HLA-A1-B8 DR3 extended haplotype (non SE) 16, 27 although in this particular population the −308A is not only associated with this extended haplotype.
The TDT was used to perform family-based association analysis on the data stratified for the presence of SE alleles and demonstrated significant association between RA and the −308A TNF 5Ј promoter SNP in individuals carrying the SE. When the data were further stratified there was a significant association between the −308A allele and RA in individuals heterozygous for the HLA-DR SE and specifically those carrying DRB1*04. These findings are in keeping with the previous findings of the H2 TNF haplotype association with RA 16 but are contrary to previous case-control studies which investigated the role of the −308 SNP in RA susceptibility and found no association. 32, 38 Interestingly, the TNF −308A allele was also found to be associated with the less common TNF H22 microsatellite haplotype which is not significantly associated with RA susceptibility. 16 This, in conjunction with the TDT analysis of the data stratified by possession of the HLA-DR SE provides evidence for the hypothesis that both the TNF −308A allele and HLA-DRB1*04 allele may contribute individually to RA susceptibility in SE heterozygotes. This finding is consistent with genetic modelling of RA which indicates that two genes located in the MHC class II and class III-IV region may act epistatically in RA. 15 Nevertheless it would be interesting to establish if −308A has the same functional effect when carried on H2 and H22.
The previous reported association between RA and the TNF H1 microsatellite haplotype (a6, b5, c1, d3, e3) has not been explained by this study. 16, 32 It is possible that a molecular explanation for the association of this haplotype and RA may lie elsewhere in the MHC class III-IV region, since genetic screens of both the TNF 5Ј promoter and 3Ј UTR have not found any H1 associated TNF SNPs. 23 Many other candidate genes are located in the class III-IV region which may influence susceptibility to RA, including the adjacent LT␣, the LT␤ and the leukocyte specific transcript (Lst-1) immunoregulatory genes. 39, 40 In the population studied, the TNF 5Ј promoter SNP −857A allele was found to influence RA susceptibility in individuals homozygous for the SE while an opposite, protective effect was provided by the TNF 5Ј promoter SNP −238A allele. These results should be viewed as preliminary since the numbers are small and they need to be confirmed in other RA populations. Nevertheless they demonstrate the potential for genetic heterogeneity even within the TNF promoter. This may explain the apparently conflicting reports of in vivo and in vitro functional analysis of the effect of the TNF −308A on TNF transcription. 27, [31] [32] [33] Furthermore, RA patients carrying the TNF −238A allele have significantly fewer joint erosions than those who are homozygous for the TNF −238G allele. 41 Both analyses, treating each subject as independent (TDT) and allowing for familial correlations that may exist from linked loci such as the class II loci, showed similar results indicating significant effects of the −308A and −857T loci.
The frequency of the TNF 5Ј promoter SNP −163A and −376A alleles found in the RA multiplex families is similar to that reported by other studies. 25, 42 indicating that these alleles occur too infrequently to play a major role in RA susceptibility in these populations. Similarly, the TNF −572A allele was only observed in a single family of Irish origin. Interestingly, this polymorphism occurs 5 bases from the K1 site which has been previously demonstrated to bind nuclear factor (NF)-KB, 43 a key inducer of TNF transcription. 44 Likewise, the −863 SNP is located within a consensus sequence for NF-KB. 45 Recently, the −863A allele has been found in both in vitro and in vivo studies to reduce levels of TNF expression significantly 33 thereby further demonstrating the heterogeneity of the TNF promoter in relation to TNF expression phenotype. Interestingly, the −863A and −1031C alleles are inherited with the TNF microsatellite haplotype 8 (a2, b1, c2, d4, e1) which has previously been associated with Crohn's disease. 46 RA is a multigenic, clinically heterogeneous disease where many genes interact to produce the final clinical phenotype. 10 By the use of TNF microsatellite and HLA-DR typing, it was possible to immunogenetically define a group of RA patients who carry SNPs in their TNF 5Ј promoter which influence their susceptibility to RA. Therefore, it appears that the influence of the TNF promoter is more complex than previously considered since we have found that individual SNPs exert specific genetic effects. In addition, the data provide a rationale for the investigation of clinical phenotypes of these specific immunogenetically defined individuals with RA and targeting anti-TNF therapy specifically to members of this group.
Methods
Thirty-three multiplex RA families (10 of Irish origin and 23 of British origin) with 175 members of whom 86 (60 female, 26 male) had RA by the American College of Rheumatology criteria 47 were included in this study. All families were Caucasian and are part of the Arthritis and
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Rheumatism Council's repository in Manchester. 48 These families had previously been typed for HLA class I and class II (HLA-DR4 subtyping by DNA oligonucleotide typing) and TNF microsatellite markers (TNFa, TNFb, TNFc, TNFd TNFe). 16 Carriage of the HLA DRB1 SE was defined as possession of the HLA-DR alleles with the L Q/R R/K A amino acid motif at positions 67, 70, 71 and 74 of the third hypervariable region.
The entire TNF promoter was amplified in two individual overlapping segments termed I (768 bp) and II (845 bp) (Figure 1 ) PCR conditions were as described previously. 16 Segment I was amplified using primers T17 (5Ј CCCACACGGAGGCATCT 3Ј) and T18 (5Ј GGGCTTGGTGGCAGGCTTGAG 3Ј) with the following annealing temperatures 94°C 1 min, 59°C 1 min, 72°C 1 min for 29 cycles followed by a final cycle of 94°C 1 min, 59°C 1 min, 72°C 5 min. Segment II was amplified with primers T19 (5Ј GGAAGCCAAGACTGAAACCA 3Ј) and T20 (5Ј CAGTATGTGAGAGGAAGAGAACC 3Ј) using the following conditions 94°C 1 min, 58°C 1 min, 72°C 1 min for 29 cycles followed by a final cycle of 94°C 1 min, 58°C 1 min, 72°C 5 min.
The PCR products of segments I and II were purified individually with QIAquick PCR purification kit (Qiagen Ltd, Dorking, UK). Automated DNA sequence analysis was carried out by primer walking (Figure 1 ) using an ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, Warrington, UK) and an ABI PRISM 310 Genetic Analyser (Perkin-Elmer). The TNF +70 polymorphism could not be reliably typed due to its position relative to primer T20 and primer A.
Bivariate association of TNF 5Ј promoter SNPs and TNF microsatellite haplotypes were examined using Pearson c2 tests. Association analysis was carried out using SPSS version 7.5 (SPSS Inc., WC, USA) with a significance level of P Ͻ 0.005. The TDT test 35, 36 was used to determine preferential transmission of alleles from heterozygous parents to RA subjects. This test comprises a joint test for association and linkage disequilibrium. In total seven loci or extended haplotypes were considered (five TNF promoter polymorphisms, TNF microsatellite haplotypes and HLA-DRB1 SE). Initially an omnibus test with permutation was applied to assess for departure from random transmission of any alleles at a locus to affected offspring. A P-value of Ͻ0.005 was taken as significant for this omnibus test. This strict level of significance was chosen to offset the multiple tests that were performed. Subsequently, any loci showing significant effects were further analysed to identify unequal transmission distortion for alleles at that locus by using Fisher's exact test and significant results were reported when P Ͻ 0.001. Again, we used a strict significance level to allow for the multiple alleles at each locus. The data was stratified for possession of the HLA-DR SE and also according to whether individuals were heterozygous or homozygous for the SE with further stratification according to SE DR subtypes DRB1*04 and DRB1*01. Analysis was performed as previously described 16 with the risk ratio from a particular allele being obtained by comparing the number of transmitted and untransmitted alleles. We further analysed the data allowing for its family structure by using the PDT. 37 Analysis using the PDT generally requires that both parents are typed for each marker and so uses less of the data than the TDT treating each child independently.
